KPIs & Operating Metrics(New)
Animal Health Revenue BreakdownBreakdown Of AssetsEmployee StatisticsGross Margin %Gross ProfitGross Profit AnnualGross Profit Annual %InventoriesLong Lived Assets By RegionNon Gaap ProfitabilityNon Gaap Profitability %Non Gaap Profitability AnnualNon Gaap Profitability Annual %Operating Expense SegregationOpex As A % Of Total Revenue %Pharmaceuticals Revenue BreakdownPharmaceuticals Revenue Breakdown AnnualPrice Change By Region %Price Change By Region Annual %Price, Volume & Rate Change Total %Property And Equipment SegregationRate Change By Region %Rate Change By Region Annual %Revenue By Business VerticalRevenue By Business Vertical %Revenue By Business Vertical AnnualRevenue By Business Vertical Annual %Revenue By Customer LocationRevenue By Customer Location %Revenue By Customer Location AnnualRevenue By Customer Location Annual %Revenue By RegionRevenue By Region AnnualRevenue By Region Annual %Revenue By SegmentRevenue By Segment %Volume Change By Region %Volume Change By Region Annual %
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLong-Term Debt IssuancesLong-Term Debt RepaymentsR&D In ProcessReceivables - NetReceivables - OtherShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuances
Ratios

Eli Lilly (LLY) Gross Profit (2016 - 2024)

Eli Lilly filings provide 18 years of Gross Profit readings, the most recent being $16.2 billion for Q1 2026.

  • On a quarterly basis, Gross Profit rose 54.44% to $16.2 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $59.8 billion, a 49.48% increase, with the full-year FY2025 number at $54.1 billion, up 47.79% from a year prior.
  • Gross Profit hit $16.2 billion in Q1 2026 for Eli Lilly, up from $15.9 billion in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $16.2 billion in Q1 2026 to a low of $5.1 billion in Q2 2022.
  • Median Gross Profit over the past 5 years was $7.6 billion (2023), compared with a mean of $9.2 billion.
  • Biggest five-year swings in Gross Profit: fell 7.05% in 2023 and later surged 57.45% in 2025.
  • Eli Lilly's Gross Profit stood at $5.8 billion in 2022, then surged by 31.49% to $7.6 billion in 2023, then skyrocketed by 47.11% to $11.1 billion in 2024, then skyrocketed by 43.04% to $15.9 billion in 2025, then increased by 1.9% to $16.2 billion in 2026.
  • The last three reported values for Gross Profit were $16.2 billion (Q1 2026), $15.9 billion (Q4 2025), and $14.6 billion (Q3 2025) per Business Quant data.